▶ 調査レポート

イムノアッセイ(免疫測定法)の世界市場:技術別(酵素、蛍光、化学発光、放射、免疫比濁法、その他)、治療対象別(心疾患、甲状腺疾患、自己免疫疾患、腫瘍、感染症、血液分析、アレルギー、その他)、地域別分析

• 英文タイトル:Global Immunoassays Market - Segmented by Technology, Therapeutics Area and End Users - Growth, Trends and Forecasts (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。イムノアッセイ(免疫測定法)の世界市場:技術別(酵素、蛍光、化学発光、放射、免疫比濁法、その他)、治療対象別(心疾患、甲状腺疾患、自己免疫疾患、腫瘍、感染症、血液分析、アレルギー、その他)、地域別分析 / Global Immunoassays Market - Segmented by Technology, Therapeutics Area and End Users - Growth, Trends and Forecasts (2018 - 2023) / B-MOR-040920資料のイメージです。• レポートコード:B-MOR-040920
• 出版社/出版日:Mordor Intelligence / 2018年2月
• レポート形態:英文、PDF、107ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Single User(1名様用)¥548,250 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥580,500 (USD4,500)▷ お問い合わせ
  Corporate User¥1,128,750 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、イムノアッセイ(免疫測定法)の世界市場について調べ、イムノアッセイ(免疫測定法)の世界規模、市場動向、市場環境、技術別(酵素、蛍光、化学発光、放射、免疫比濁法、その他)分析、治療対象別(心疾患、甲状腺疾患、自己免疫疾患、腫瘍、感染症、血液分析、アレルギー、その他)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・イムノアッセイ(免疫測定法)の世界市場インサイト
・イムノアッセイ(免疫測定法)の世界市場環境
・イムノアッセイ(免疫測定法)の世界市場動向
・イムノアッセイ(免疫測定法)の世界市場規模
・イムノアッセイ(免疫測定法)の世界市場規模:技術別(酵素、蛍光、化学発光、放射、免疫比濁法、その他)
・イムノアッセイ(免疫測定法)の世界市場規模:治療対象別(心疾患、甲状腺疾患、自己免疫疾患、腫瘍、感染症、血液分析、アレルギー、その他)
・イムノアッセイ(免疫測定法)の世界市場:地域別市場規模・分析
・イムノアッセイ(免疫測定法)の北米市場規模・予測
・イムノアッセイ(免疫測定法)のアメリカ市場規模・予測
・イムノアッセイ(免疫測定法)のヨーロッパ市場規模・予測
・イムノアッセイ(免疫測定法)のアジア市場規模・予測
・イムノアッセイ(免疫測定法)の日本市場規模・予測
・イムノアッセイ(免疫測定法)の中国市場規模・予測
・イムノアッセイ(免疫測定法)のインド市場規模・予測
・イムノアッセイ(免疫測定法)の韓国市場規模・予測
・関連企業情報・競争状況

The global Immunoassay market has been estimated to reach 17.16 billion in 2017. : The global Immunoassays market is expected to register a CAGR of 9.7% during the forecast period, 2018 to 2023. North America dominates the market due to the technological advancement in the immunoassay products and rising incidence in the chronic diseases like thyroid, cardiovascular diseases.

High Sensitivity and Specificity

Compared to conventional tests, immunoassays have been proven to provide highly accurate results even with very small samples. Immunoassays are considered to have a detection limit of 1pg/ml. This can be attributed to the fact that immunoassays are based entirely on immunologic reactions. Immunologic reactions are highly specific as they can take place only in the presence of proper immunologic agents. Immunoassays have a range of applications in pharmaceutical analysis such as diagnosis of disease, therapeutic drug monitoring, clinical pharmacokinetics and bioequivalence in drug discovery and pharmaceutical industries.
Additionally, cost effectives and rapid analysis by the immunoassays and growth in the biotechnology and pharmaceutical sectors are also driving the growth of the Global Immunoassays Market.

Limitations Associated with Immunoassay

Immunoassays have shown high sensitivity and specificity. While this have advantages, there have been many limitations associated with the procedure. The limit of detection (LOD) for most of the immunoassays is limited primarily by the signal-to-noise ratio provided by the instrument that is used to detect antibody-antigen binding or by non-specific binding (NSB). Immunoassays are very complex to develop and manufacture and employs complex biomolecules such as antibodies, antigens and enzymes for the detection of the target molecules. Additionally, complex assay procedures are also acting as a restraint for the global immunoassays market.

North America to Dominate the Market

The market has been segmented by technology into enzyme immunoassay, fluorescence immunoassay, chemiluminescence immunoassay, radioimmunoassay, nephelometric immunoassay, and others. Based on therapeutic areas, it has been segmented into cardiology, thyroid, autoimmune disease, oncology, infectious disease, hematology, allergy, and others. By end user, the market is segmented into hospital, centralized laboratory, academic institution, pharma & biotech firm, contract research organization, and others. The market is segmented on the basis of geography into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The regions have been further divided into major constituent countries.
North America dominates the Global Immunoassays Market which is mainly driven by increasing incidence of chronic disease and use of immunoassays in oncology.

Key Developments in the Market

• September 2017: Meridian Life science Inc. launches TRUBlock Ultra which is an active immunoassay interference blocker created by HAMA, rheumatoid factor (RH) and heterophillic antibodies (HA).
• June 2017: Qiagen developed QFT-Plus which detects latent tuberculosis infection got FDA approval.

Key Players: ABBOTT LABORATORIES INC., BECTON DICKINSON AND COMPANY, DANAHER CORPORATION (BECKMAN COULTER), EDP BIOTECH CORPORATION, HOLOGIC (GEN-PROBE), LUMINEX CORPORATION, MERIDIAN LIFE SCIENCE INC., QIAGEN

REASONS TO PURCHASE THIS REPORT

• Current and future Immunoassays Market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.

CUSTOMIZATION OF THE REPORT

• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

レポート目次

TABLE OF CONTENTS
1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTERS FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 HIGH SENSITIVITY AND SPECIFICITY
6.1.2 COST EFFECTIVENESS
6.1.3 RAPID ANALYSIS BY THE IMMUNOASSAYS
6.1.4 GROWTH IN THE BIOTECHNOLOGY AND PHARMACEUTICAL SECTORS
6.2 MARKET RESTRAINTS
6.2.1 COMPLICATED REGULATORY REQUIREMENTS
6.2.2 COMPLEX ASSAY PROCEDURES
6.2.3 LIMITATIONS ASSOCIATED WITH IMMUNOASSAY
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 BY TECHNOLOGY
7.1.1 ENZYME IMMUNOASSAY
7.1.2 FLUORESCENCE IMMUNOASSAY
7.1.3 CHEMILUMINESCENCE IMMUNOASSAY
7.1.4 RADIOIMMUNOASSAY
7.1.5 NEPHELOMETRIC IMMUNOASSAY
7.1.6 OTHERS
7.2 BY THERAPEUTIC AREA
7.2.1 CARDIOLOGY
7.2.2 THYROID
7.2.3 AUTOIMMUNE DISEASE
7.2.4 ONCOLOGY
7.2.5 INFECTIOUS DISEASE
7.2.6 HEMATOLOGY
7.2.7 ALLERGY
7.2.8 OTHERS
7.3 BY END USER
7.3.1 HOSPITAL
7.3.2 CENTRALIZED LABORATORY
7.3.3 ACADEMIC INSTITUTION
7.3.4 PHARMA & BIOTECH FIRM
7.3.5 CONTRACT RESEARCH ORGANIZATION
7.3.6 OTHERS
7.4 SEGEMENTATION BY GEOGRAPHY
7.4.1 NORTH AMERICA
7.4.1.1 UNITED STATES
7.4.1.2 CANADA
7.4.1.3 MEXICO
7.4.2 EUROPE
7.4.2.1 FRANCE
7.4.2.2 GERMANY
7.4.2.3 UNITED KINGDOM
7.4.2.4 ITALY
7.4.2.5 SPAIN
7.4.2.6 REST OF EUROPE
7.4.3 ASIA-PACIFIC
7.4.3.1 CHINA
7.4.3.2 JAPAN
7.4.3.3 INDIA
7.4.3.4 AUSTRALIA & NEW ZEALAND
7.4.3.5 SOUTH KOREA
7.4.3.6 REST OF ASIA-PACIFIC
7.4.4 MIDDLE EAST AND AFRICA
7.4.4.1 GCC
7.4.4.2 SOUTH AFRICA
7.4.4.3 REST OF MIDDLE EAST AND AFRICA
7.4.5 SOUTH AMERICA
7.4.5.1 BRAZIL
7.4.5.2 ARGENTINA
7.4.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. COMPANY PROFILES
9.1 ABBOTT LABORATORIES INC
9.2 BECTON DICKINSON AND COMPANY
9.3 DANAHER CORPORATION

9.4 EDP BIOTECH CORPORATION
9.5 HOLOGIC
9.6 LUMINEX CORPORATION
9.7 MERIDIAN LIFE SCIENCE INC
9.8 QIAGEN
10. FUTURE OUTLOOK OF THE MARKET